| abstract |
Problem: To provide a pharmaceutical composition for prevention or treatment of urinary track organ cancer. The composition does not cause a problem with respect to side effects, can be continually used for an extended period of time, and is administered to a urinary track organ by injection into a cavity of the urinary track organ. Solution: a solution configured to be injected into a cavity of a urinary track organ, the solution containing D-allose. The urinary track organ cavity is inside the upper urinary tract and inside the bladder. The solution is for injection therapy where the solution is injected into a cavity of a urinary track organ, and for utilization of increase in D-allose sugar intake into urinary track organ cancer cells (e.g. RT112, 253J, J82). The solution contains D-allose together with a pharmaceutically acceptable dilution agent or support. This pharmaceutical composition is for prevention or treatment of cancers in a urinary track organ. |